Product name
Vaccine against H5N1 infection based on recombinant modified vaccinia virus Ankara MVASummary
Recombinant MVA-Virus, expressing the HA-gene sequence of H5N1 influenza virus induces a broad antibody responseOrganization name
ipal GmbHProfile
Recombinant Modified vaccinia virus Ankara (MVA) is a safety-tested vaccine against infectious diseases and cancer. The novel technology is based on the expression of hemagglutinin- (HA) gene in a MVA-Vector. Immunization with the recombinant MVA-Virus, expressing the HA-gene sequence of H5N1 influenza virus induced a broad antibody response in a mouse model. Additionally protection against different strains of H5N1 viruses was obtained.
The vaccine can be used against H5N1 infection for pre-pandemic use and for prophylactic and/or therapeutic vaccination. Furthermore a treatment of the avian flu in humans as well as other animals is possible.
Competitiveness
- Until now, no approved vaccine against H5N1 available.
- No additional product, like adjuvants and no high doses are required.
- Established safety profile of MVA in humans reduces previous additional product characterization (as needed for development of conventional inactivated vaccine preparations).
- Good immunogenicity, extreme host-range restriction and easy production in chicken embryo fibroblasts and baby hamster kidney cells promise the possibility of large scale vaccine production under GMP requirements.
- The use of MVA-based vaccine overcomes the so far problem of limited and insufficient global production of sufficient quantities for a world-wide H5N1 vaccination campaign.
International patents have been filed.
The invention was made at the Paul Ehrlich Institute, Langen and is offered by IPAL.
Contact
Rafaela Kunz
rafaela.kunz(at)ipal.de
About ipal GmbH
The ipal GmbH patent agency assesses and markets the inventions of scientists in the area of Life Sciences and Physics & Engineering from Charité-Universitätsmedizin (University Medicine), Robert Koch Institute, Deutsches Herzzentrum (German Heart Institute), Bundesanstalt für Materialprüfung (BAM - Federal Institute for Materials Research and Testing), the Zuse Institute as well as the Paul Ehrlich Institute, Langen and the Jacobs University Bremen. IPAL provides all of the services necessary - from the assessment of patentable technologies to a comprehensive patent protection all the way to the evaluation of sales returns potentials on the market and successful commercialisation through the use of licensing agreements.


print this page